AI entity
ai-research is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Leptin, the most common co-covered peer. Source depth averages 6 original sources per story, versus 2.4 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ai-research is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Leptin, the most common co-covered peer. Source depth averages 6 original sources per story, versus 2.4 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 6.8 for that window. We currently track 1 AI story that mention GLP-1 Agonists, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 36 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GLP-1 Agonists. Shared-story counts are live from our verified record — not editorial picks.
Researchers at the University of Pittsburgh have unveiled a novel AI-driven approach to obesity drug development focused on restoring leptin sensitivity. This computational method identifies small molecules capable of bypassing leptin resistance, potentially offering a more targeted alternative to current GLP-1 therapies.
GLP-1 Agonists is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
